# OnCo record idea-tr2-ctdna-mrd-qualification (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-tr2-ctdna-mrd-qualification/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-tr2-ctdna-mrd-qualification" ;
  schema:name "Formally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials"@en ;
  schema:description "If a blood test reliably shows whether cancer will come back after surgery, trials could use it instead of waiting years for relapse. Regulators have a process to bless such a test; oncology should use it."@en ;
  schema:url <https://onco.cc/ideas/idea-tr2-ctdna-mrd-qualification/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/biomarker-qualification-program> ;
  onco:related <https://onco.cc/ideas/idea-ctdna-guided-adjuvant-crc/>, <https://onco.cc/pairings/ctdna-mrd-to-adjuvant/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:drugs <https://onco.cc/drugs/signatera/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/> ;
  onco:trials <https://onco.cc/trials/imvigor011/>, <https://onco.cc/trials/dynamic/>, <https://onco.cc/trials/circulate-japan/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-dormancy-mrd/> .